Cargando…
Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials fai...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882886/ https://www.ncbi.nlm.nih.gov/pubmed/29615724 http://dx.doi.org/10.1038/s41598-018-22938-x |
_version_ | 1783311544708235264 |
---|---|
author | Liu, Yang Pejchinovski, Martin Wang, Xueqi Fu, Xuebin Castelletti, Deborah Watnick, Terry J. Arcaro, Alexandre Siwy, Justyna Mullen, William Mischak, Harald Serra, Andreas L. |
author_facet | Liu, Yang Pejchinovski, Martin Wang, Xueqi Fu, Xuebin Castelletti, Deborah Watnick, Terry J. Arcaro, Alexandre Siwy, Justyna Mullen, William Mischak, Harald Serra, Andreas L. |
author_sort | Liu, Yang |
collection | PubMed |
description | Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials failed to prove efficacy of mTOR inhibitor treatment. Here, we demonstrate that treatment with mTOR inhibitors result in the removal of negative feedback loops and up-regulates pro-proliferative phosphatidylinositol 3-kinase (PI3K)-Akt and PI3K-extracellular signal-regulated kinase (ERK) signaling in rat and mouse PKD models. Dual mTOR/PI3K inhibition with NVP-BEZ235 abrogated these pro-proliferative signals and normalized kidney morphology and function by blocking proliferation and fibrosis. Our findings suggest that multi-target PI3K/mTOR inhibition may represent a potential treatment for ADPKD. |
format | Online Article Text |
id | pubmed-5882886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58828862018-04-09 Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease Liu, Yang Pejchinovski, Martin Wang, Xueqi Fu, Xuebin Castelletti, Deborah Watnick, Terry J. Arcaro, Alexandre Siwy, Justyna Mullen, William Mischak, Harald Serra, Andreas L. Sci Rep Article Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the development of kidney cysts leading to kidney failure in adulthood. Inhibition of mammalian target of rapamycin (mTOR) slows polycystic kidney disease (PKD) progression in animal models, but randomized controlled trials failed to prove efficacy of mTOR inhibitor treatment. Here, we demonstrate that treatment with mTOR inhibitors result in the removal of negative feedback loops and up-regulates pro-proliferative phosphatidylinositol 3-kinase (PI3K)-Akt and PI3K-extracellular signal-regulated kinase (ERK) signaling in rat and mouse PKD models. Dual mTOR/PI3K inhibition with NVP-BEZ235 abrogated these pro-proliferative signals and normalized kidney morphology and function by blocking proliferation and fibrosis. Our findings suggest that multi-target PI3K/mTOR inhibition may represent a potential treatment for ADPKD. Nature Publishing Group UK 2018-04-03 /pmc/articles/PMC5882886/ /pubmed/29615724 http://dx.doi.org/10.1038/s41598-018-22938-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Liu, Yang Pejchinovski, Martin Wang, Xueqi Fu, Xuebin Castelletti, Deborah Watnick, Terry J. Arcaro, Alexandre Siwy, Justyna Mullen, William Mischak, Harald Serra, Andreas L. Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
title | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
title_full | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
title_fullStr | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
title_full_unstemmed | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
title_short | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
title_sort | dual mtor/pi3k inhibition limits pi3k-dependent pathways activated upon mtor inhibition in autosomal dominant polycystic kidney disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882886/ https://www.ncbi.nlm.nih.gov/pubmed/29615724 http://dx.doi.org/10.1038/s41598-018-22938-x |
work_keys_str_mv | AT liuyang dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT pejchinovskimartin dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT wangxueqi dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT fuxuebin dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT castellettideborah dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT watnickterryj dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT arcaroalexandre dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT siwyjustyna dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT mullenwilliam dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT mischakharald dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease AT serraandreasl dualmtorpi3kinhibitionlimitspi3kdependentpathwaysactivateduponmtorinhibitioninautosomaldominantpolycystickidneydisease |